Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

146 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Roles of NGAL and MMP-9 in the tumor microenvironment and sensitivity to targeted therapy.
Candido S, Abrams SL, Steelman LS, Lertpiriyapong K, Fitzgerald TL, Martelli AM, Cocco L, Montalto G, Cervello M, Polesel J, Libra M, McCubrey JA. Candido S, et al. Among authors: steelman ls. Biochim Biophys Acta. 2016 Mar;1863(3):438-448. doi: 10.1016/j.bbamcr.2015.08.010. Epub 2015 Aug 14. Biochim Biophys Acta. 2016. PMID: 26278055 Free article. Review.
Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance.
McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F, Lehmann B, Terrian DM, Milella M, Tafuri A, Stivala F, Libra M, Basecke J, Evangelisti C, Martelli AM, Franklin RA. McCubrey JA, et al. Among authors: steelman ls. Biochim Biophys Acta. 2007 Aug;1773(8):1263-84. doi: 10.1016/j.bbamcr.2006.10.001. Epub 2006 Oct 7. Biochim Biophys Acta. 2007. PMID: 17126425 Free PMC article. Review.
Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging.
Steelman LS, Chappell WH, Abrams SL, Kempf RC, Long J, Laidler P, Mijatovic S, Maksimovic-Ivanic D, Stivala F, Mazzarino MC, Donia M, Fagone P, Malaponte G, Nicoletti F, Libra M, Milella M, Tafuri A, Bonati A, Bäsecke J, Cocco L, Evangelisti C, Martelli AM, Montalto G, Cervello M, McCubrey JA. Steelman LS, et al. Aging (Albany NY). 2011 Mar;3(3):192-222. doi: 10.18632/aging.100296. Aging (Albany NY). 2011. PMID: 21422497 Free PMC article. Review.
Involvement of Akt-1 and mTOR in sensitivity of breast cancer to targeted therapy.
Sokolosky ML, Stadelman KM, Chappell WH, Abrams SL, Martelli AM, Stivala F, Libra M, Nicoletti F, Drobot LB, Franklin RA, Steelman LS, McCubrey JA. Sokolosky ML, et al. Among authors: steelman ls. Oncotarget. 2011 Jul;2(7):538-50. doi: 10.18632/oncotarget.302. Oncotarget. 2011. PMID: 21730367 Free PMC article.
Increased NGAL (Lnc2) expression after chemotherapeutic drug treatment.
Chappell WH, Abrams SL, Stadelman KM, LaHair MM, Franklin RA, Cocco L, Evangelisti C, Chiarini F, Martelli AM, Steelman LS, McCubrey JA. Chappell WH, et al. Among authors: steelman ls. Adv Biol Regul. 2013 Jan;53(1):146-55. doi: 10.1016/j.jbior.2012.09.004. Epub 2012 Sep 16. Adv Biol Regul. 2013. PMID: 23073564 No abstract available.
Effects of ectopic expression of NGAL on doxorubicin sensitivity.
Chappell WH, Abrams SL, Montalto G, Cervello M, Martelli AM, Candido S, Libra M, Polesel J, Talamini R, Arlinghaus R, Steelman LS, McCubrey JA. Chappell WH, et al. Among authors: steelman ls. Oncotarget. 2012 Oct;3(10):1236-45. doi: 10.18632/oncotarget.691. Oncotarget. 2012. PMID: 23100449 Free PMC article.
Ectopic NGAL expression can alter sensitivity of breast cancer cells to EGFR, Bcl-2, CaM-K inhibitors and the plant natural product berberine.
Chappell WH, Abrams SL, Franklin RA, LaHair MM, Montalto G, Cervello M, Martelli AM, Nicoletti F, Candido S, Libra M, Polesel J, Talamini R, Milella M, Tafuri A, Steelman LS, McCubrey JA. Chappell WH, et al. Among authors: steelman ls. Cell Cycle. 2012 Dec 1;11(23):4447-61. doi: 10.4161/cc.22786. Epub 2012 Nov 16. Cell Cycle. 2012. PMID: 23159854 Free PMC article.
146 results